Pharsight

Aprecia Pharms patents expiration

1. Spritam patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463160 APRECIA PHARMS Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
Feb, 2018

(6 years ago)

US6471992 APRECIA PHARMS Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
Feb, 2018

(6 years ago)

US9669009 APRECIA PHARMS Rapid disperse dosage form containing levetiracetam
Mar, 2034

(9 years from now)

US11160786 APRECIA PHARMS Rapid disperse dosage form
Mar, 2034

(9 years from now)

US9339489 APRECIA PHARMS Rapid disperse dosage form containing levetiracetam
Mar, 2034

(9 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 31 July, 2015

Treatment: Method of administering levetiracetam under fasted conditions; Method of administering levetiracetam

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

SPRITAM family patents

Family Patents